Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 1b, Open-label Study of Etentamig (ABBV-383) Administered Subcutaneously in Subjects With Relapsed or Refractory Multiple Myeloma

NCT06223516 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06223516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06223516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 1b, Open-label Study of Etentamig (ABBV-383) Administered Subcutaneously in Subjects With Relapsed or Refractory Multiple Myeloma
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 17, 2024
Completion date
December 31, 2027
Enrollment
60 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma